Phase I trial of cytarabine and hydroxyurea.
A combination of hydroxyurea (HU) and cytarabine (ara-C) can overcome ara-C resistance in vitro. To determine the pattern of toxicity of this combination, 22 patients with refractory leukemia and lymphoma were treated for 5 days with ara-C (100 mg/m2/day by constant infusion) and escalating doses of HU (0.375-1.77 g/m2 every 6 hours). Hematologic toxicity was severe even at the lowest HU dose level. Skin and mucosal toxic effects were frequent but not dose-limiting. No novel types of toxic effects were observed.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001772:Blood Cell Count; D002648:Child; D003561:Cytarabine / Q000008:administration & dosage; D004341:Drug Evaluation; D004351:Drug Resistance; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage; D007938:Leukemia / Q000188:drug therapy*; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012871:Skin Diseases / Q000139:chemically induced
D003561:Cytarabine; D006918:Hydroxyurea